BR112012004916A2 - composições sns-595 estáveis e métodos de preparação - Google Patents

composições sns-595 estáveis e métodos de preparação

Info

Publication number
BR112012004916A2
BR112012004916A2 BR112012004916A BR112012004916A BR112012004916A2 BR 112012004916 A2 BR112012004916 A2 BR 112012004916A2 BR 112012004916 A BR112012004916 A BR 112012004916A BR 112012004916 A BR112012004916 A BR 112012004916A BR 112012004916 A2 BR112012004916 A2 BR 112012004916A2
Authority
BR
Brazil
Prior art keywords
compositions
sns
preparation methods
stable
stable sns
Prior art date
Application number
BR112012004916A
Other languages
English (en)
Inventor
Hashash Ahmad
Sudhakar Anantha
Cheng Hengqin
Jacobs Jeff
Ritchie Sean
Original Assignee
Sunesis Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sunesis Pharmaceuticals Inc filed Critical Sunesis Pharmaceuticals Inc
Publication of BR112012004916A2 publication Critical patent/BR112012004916A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Compositions Of Macromolecular Compounds (AREA)

Abstract

''composições sns-595 estáveis e métodos de preparação'' trata-se de métodos de preparo da substância sns-595 substancialmente pura. também são fornecidas composições que compreendem a substância sns-595 que são substancialmente puras e essencialmente livres de partículas visíveis.
BR112012004916A 2009-09-04 2010-09-03 composições sns-595 estáveis e métodos de preparação BR112012004916A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US24016109P 2009-09-04 2009-09-04
PCT/US2010/047776 WO2011028979A1 (en) 2009-09-04 2010-09-03 Stable sns-595 compositions and methods of preparation

Publications (1)

Publication Number Publication Date
BR112012004916A2 true BR112012004916A2 (pt) 2017-07-04

Family

ID=42990341

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112012004916A BR112012004916A2 (pt) 2009-09-04 2010-09-03 composições sns-595 estáveis e métodos de preparação

Country Status (26)

Country Link
US (5) US8586601B2 (pt)
EP (2) EP2674431A1 (pt)
JP (3) JP6339315B2 (pt)
KR (3) KR20180112103A (pt)
CN (2) CN102596948B (pt)
AU (1) AU2010289337B2 (pt)
BR (1) BR112012004916A2 (pt)
CA (2) CA3002440A1 (pt)
CL (1) CL2012000565A1 (pt)
CO (1) CO6511211A2 (pt)
DK (1) DK2473507T3 (pt)
EA (2) EA201400683A1 (pt)
ES (1) ES2462502T3 (pt)
HK (1) HK1172032A1 (pt)
HR (1) HRP20140372T1 (pt)
IL (3) IL218404A (pt)
MX (1) MX2012002573A (pt)
NZ (2) NZ598467A (pt)
PH (1) PH12014500714A1 (pt)
PL (1) PL2473507T3 (pt)
PT (1) PT2473507E (pt)
SG (3) SG10201808097QA (pt)
TW (2) TWI519535B (pt)
UA (1) UA110465C2 (pt)
WO (1) WO2011028979A1 (pt)
ZA (1) ZA201201469B (pt)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005089757A1 (en) 2004-03-15 2005-09-29 Sunesis Pharmaceuticals, Inc. Sns-595 and methods of using the same
WO2008016678A2 (en) * 2006-08-01 2008-02-07 Sunesis Pharmaceuticals, Inc. Pharmaceutical dosage forms for (+)-1,4-dihydro-7-[(3s,4s)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid
EP3141250A1 (en) 2007-10-22 2017-03-15 Sunesis Pharmaceuticals, Inc. Methods of using (+)-1,4-dihydro-7-[(3s,4s)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid in combination therapy
AU2008335772B2 (en) 2007-12-10 2014-11-27 Sunesis Pharmaceuticals, Inc. Methods of using (+)-1,4-dihydro-7-[(3S,4S)-3- methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1- (2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid for treatment of antecedent hematologic disorders
MX2011006974A (es) 2008-12-31 2011-11-18 Sunesis Pharmaceuticals Inc Metodo para preparar acido (+)-1,4-dihidro-7-[(3s,4s)-3-metoxi-4-( metilamino)-1-pirrolidinil]-4-oxo-1-) (2-tiazolil)-1, 8-naftiridin-3-carboxilico.
UA110465C2 (en) 2009-09-04 2016-01-12 Sunesis Pharmaceutecals Inc Stable sns-595 composition

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6233176A (ja) * 1985-08-05 1987-02-13 Toyama Chem Co Ltd １，４−ジヒドロ−４−オキソナフチリジン誘導体およびその塩
NZ287139A (en) * 1994-06-14 1997-07-27 Dainippon Pharmaceutical Co Naphthyridine derivatives; preparative process and anti-tumour medicaments
JPH10173986A (ja) 1996-12-16 1998-06-26 Sony Corp 移動体撮影装置
JP4294121B2 (ja) 1998-06-05 2009-07-08 大日本住友製薬株式会社 ピリドンカルボン酸誘導体の製造方法およびその中間体
JP4178783B2 (ja) 2001-10-19 2008-11-12 三菱化学株式会社 光学記録媒体
WO2005089757A1 (en) 2004-03-15 2005-09-29 Sunesis Pharmaceuticals, Inc. Sns-595 and methods of using the same
US8580814B2 (en) 2006-04-03 2013-11-12 Sunesis Pharmaceuticals, Inc. Methods of using (+)-1,4-dihydro-7-[(3S,4S)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4- oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid for treatment of cancer
EP2043645A2 (en) * 2006-06-12 2009-04-08 Sunesis Pharmaceuticals, Inc. Compounds and compositions for treatment of cancer
WO2008016678A2 (en) 2006-08-01 2008-02-07 Sunesis Pharmaceuticals, Inc. Pharmaceutical dosage forms for (+)-1,4-dihydro-7-[(3s,4s)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid
EP2049109B1 (en) 2006-08-02 2015-11-18 Sunesis Pharmaceuticals, Inc. Combined use of (+)-1,4-dihydro-7-[(3s,4s)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid and cytarabine (ara-c) for the treatment of leukemia
EP3141250A1 (en) 2007-10-22 2017-03-15 Sunesis Pharmaceuticals, Inc. Methods of using (+)-1,4-dihydro-7-[(3s,4s)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid in combination therapy
AU2008335772B2 (en) 2007-12-10 2014-11-27 Sunesis Pharmaceuticals, Inc. Methods of using (+)-1,4-dihydro-7-[(3S,4S)-3- methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1- (2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid for treatment of antecedent hematologic disorders
MX2011006974A (es) 2008-12-31 2011-11-18 Sunesis Pharmaceuticals Inc Metodo para preparar acido (+)-1,4-dihidro-7-[(3s,4s)-3-metoxi-4-( metilamino)-1-pirrolidinil]-4-oxo-1-) (2-tiazolil)-1, 8-naftiridin-3-carboxilico.
CN102405045A (zh) 2009-02-27 2012-04-04 逊尼希思制药公司 利用sns-595 治疗具有降低的brca2 活性的癌症对象的方法
UA110465C2 (en) 2009-09-04 2016-01-12 Sunesis Pharmaceutecals Inc Stable sns-595 composition
US8470817B2 (en) 2009-10-26 2013-06-25 Sunesis Pharmaceuticals, Inc. Compounds and methods for treatment of cancer

Also Published As

Publication number Publication date
IL237724A (en) 2016-10-31
NZ598467A (en) 2014-04-30
TWI615391B (zh) 2018-02-21
US9969730B2 (en) 2018-05-15
NZ623780A (en) 2015-10-30
CN102596948B (zh) 2015-07-22
US9469635B2 (en) 2016-10-18
KR20120078711A (ko) 2012-07-10
SG178956A1 (en) 2012-04-27
US20110082169A1 (en) 2011-04-07
IL218404A0 (en) 2012-04-30
MX2012002573A (es) 2012-04-10
EP2473507B1 (en) 2014-03-19
IL247929B (en) 2018-01-31
ZA201201469B (en) 2013-05-29
CA2772291A1 (en) 2011-03-10
EP2473507A1 (en) 2012-07-11
EP2674431A1 (en) 2013-12-18
AU2010289337B2 (en) 2014-10-30
US8586601B2 (en) 2013-11-19
KR20180112103A (ko) 2018-10-11
CN104177359B (zh) 2018-06-01
WO2011028979A1 (en) 2011-03-10
TW201114767A (en) 2011-05-01
CN104177359A (zh) 2014-12-03
SG2014013163A (en) 2014-09-26
CA3002440A1 (en) 2011-03-10
CN102596948A (zh) 2012-07-18
PT2473507E (pt) 2014-05-23
DK2473507T3 (da) 2014-04-22
JP2018127457A (ja) 2018-08-16
CL2012000565A1 (es) 2012-12-07
IL218404A (en) 2015-07-30
AU2010289337A1 (en) 2012-03-22
SG10201808097QA (en) 2018-10-30
PH12014500714B1 (en) 2015-09-07
EA201270377A1 (ru) 2013-01-30
PH12014500714A1 (en) 2015-09-07
US20190084978A1 (en) 2019-03-21
JP2016104769A (ja) 2016-06-09
US20170226104A1 (en) 2017-08-10
JP6339315B2 (ja) 2018-06-06
TWI519535B (zh) 2016-02-01
UA110465C2 (en) 2016-01-12
HK1172032A1 (en) 2013-04-12
KR20170102568A (ko) 2017-09-11
US20140275547A1 (en) 2014-09-18
EA201400683A1 (ru) 2015-05-29
JP2013503899A (ja) 2013-02-04
HRP20140372T1 (hr) 2014-06-20
ES2462502T3 (es) 2014-05-23
KR101811763B1 (ko) 2017-12-22
US20110086876A1 (en) 2011-04-14
TW201504240A (zh) 2015-02-01
PL2473507T3 (pl) 2014-08-29
CO6511211A2 (es) 2012-08-31
US8138202B2 (en) 2012-03-20

Similar Documents

Publication Publication Date Title
PH12013502192A1 (en) Antibodies against human angiopoietin 2
MX2012007161A (es) Derivados fenolicos y su uso farmaceutico o cosmetico.
MX2012007098A (es) Derivados fenolicos y su uso farmaceutico o cosmetico.
CR9339A (es) Formas farmaceuticas con propiedades farmacocineticas mejoradas
MY152711A (en) Oral compositions containing a combination of natural extracts and related methods
BR112012013664A2 (pt) rabdovírus oncolítico
BR112012004916A2 (pt) composições sns-595 estáveis e métodos de preparação
MX2019012939A (es) Formulaciones que contienen linaclotida para administracion oral.
UY32704A (es) Compuestos de 2,3-dihidro-1h-indeno
MY161868A (en) Anti-bv8 antibodies and uses thereof
ECSP099791A (es) Derivados de 7-alquinil-1,8-naftiridonas, su preparación y su aplicación en terapéutica
WO2012097116A3 (en) Isotopologues of isoindole derivatives
CL2012003265A1 (es) Polisacarido de semillas de tamarindo para usarse en el tratamiento de enfermedades infecciosas; composicion farmacéutica y/o dermocosmética antiinflamatoria que contiene dicho polisacárido; uso de un polisacárido de semilla de tamarindo.
MX2012010127A (es) Derivados de aminoindanos, su preparacion y su aplicacion en terapeuticos.
MX2011006721A (es) Formulacion farmaceutica de fenofibrato nanonizado.
CL2012001759A1 (es) Compuestos derivados de 8-hidroxiquinolina-7-carboxamida; composicion farmaceutica.
ECSP10010292A (es) Nuevos derivados de ácido 2-mercaptociclopentanocarboxílico, su procedimiento de preparación y las composiciones farmacéuticas que los contienen
IN2012DN06607A (pt)
UY32154A (es) Derivados de isoquinolinona, procesos para su preparacion, composiciones farmaceuticas que los contiene y su uso en terapia
TW200833350A (en) The methods of preparation of Calamus quiquesetinervius Burret extracts
CU23738B7 (es) Formas farmacéuticas con propiedades farmacocinéticas mejoradas
CO6390001A2 (es) Anticuerpos contra la angiopoyetina 2 humana
TR200806304A2 (tr) Çözünürlük artırıcı farmasötik bileşim
TR200806305A2 (tr) Çözünürlük ve stabilite artırıcı farmasötik bileşim
UA35660U (en) Use of antihomotoxic preparations as cytoprotectors

Legal Events

Date Code Title Description
B15I Others concerning applications: loss of priority

Free format text: PERDA DA PRIORIDADE US 61/240,161 DE 04/09/2009 REIVINDICADA NO PCT/US2010/047776, CONFORME AS DISPOSICOES PREVISTAS NA LEI 9.279 DE 14/05/1996 (LPI) ART. 16 7O, ITEM 28 DO ATO NORMATIVO 128/97 E NO ART. 29 DA RESOLUCAO INPI-PR 77/2013. ESTA PERDA SE DEU PELO FATO DE O DEPOSITANTE CONSTANTE DA PETICAO DE REQUERIMENTO DO PEDIDO PCT ("SUNESIS PHARMACEUTICALS, INC") SER DISTINTO DAQUELES QUE DEPOSITARAM A PRIORIDADE REIVINDICADA E NAO FOI APRESENTADO O DOCUMENTO COMPROBATORIO DE CESSAO, CONFORME AS DISPOSICOES PREVISTAS NA LEI 9.279 DE 14/05/1996 (LPI) ART. 16 6O, ITEM 27 DO ATO NORMATIVO 128/97 E NO ART. 2 DA RESOLUCAO INPI-PR 179/2017.

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B15K Others concerning applications: alteration of classification

Free format text: AS CLASSIFICACOES ANTERIORES ERAM: C07D 417/04 , C07D 417/14

Ipc: C07D 417/04 (2006.01), C07D 417/14 (2006.01), A61K

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 11A ANUIDADE.

B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements